Cargando…
Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections
Background and Objectives: The identification of possible biomarkers that can predict treatment response among DME eyes is important for the individualization of treatment plans. We investigated optical coherence tomography (OCT)-based biomarkers that may predict the one-year real-life outcomes amon...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053215/ https://www.ncbi.nlm.nih.gov/pubmed/36984630 http://dx.doi.org/10.3390/medicina59030629 |
_version_ | 1785015359930105856 |
---|---|
author | Chang, Yen-Chieh Huang, Yu-Te Hsu, Alan Y. Meng, Ping-Ping Lin, Chun-Ju Lai, Chun-Ting Hsia, Ning-Yi Chen, Huan-Sheng Tien, Peng-Tai Lin, Jane-Ming Chen, Wen-Lu Tsai, Yi-Yu |
author_facet | Chang, Yen-Chieh Huang, Yu-Te Hsu, Alan Y. Meng, Ping-Ping Lin, Chun-Ju Lai, Chun-Ting Hsia, Ning-Yi Chen, Huan-Sheng Tien, Peng-Tai Lin, Jane-Ming Chen, Wen-Lu Tsai, Yi-Yu |
author_sort | Chang, Yen-Chieh |
collection | PubMed |
description | Background and Objectives: The identification of possible biomarkers that can predict treatment response among DME eyes is important for the individualization of treatment plans. We investigated optical coherence tomography (OCT)-based biomarkers that may predict the one-year real-life outcomes among diabetic macular edema (DME) eyes following treatment by intravitreal ranibizumab (IVR) injections. Materials and Methods: A total of 65 eyes from 35 treatment-naïve patients with DME treated with ranibizumab injection were recruited. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP), and OCT scans were retrospectively recorded at baseline before treatment and at 3 months, 6 months, and 12 months after treatment. The OCT scans were evaluated for biomarkers of interest, which included central retinal thickness (CRT), amount and locations of hyperreflective foci (HRF), subretinal fluid (SRF), intraretinal cysts (IRC), large outer nuclear layer cyst (LONLC), ellipsoid zone disruption (EZD), disorganization of retinal inner layers (DRIL), hard exudates (HE), epiretinal membrane (ERM), and vitreomacular interface (VMI). Correlations between these OCT biomarkers and outcome measures (visual and structural) were statistically analyzed. Results: A total of 65 eyes from 35 patients with DME were enrolled. The mean age was 64.2 ± 10.9 years old. Significant improvement in terms of mean BCVA (p < 0.005) and mean CRT was seen at final follow-up compared to baseline. The biomarkers of DRIL, LONLC, and SRF were found to be predictive for at least 50 μm CRT reduction after treatment (with odds ratio of 8.69, 8.5, and 17.58, respectively). The biomarkers of IRC, LONLC, and SRF were predictive for significant improvement in terms of BCVA and CRT after treatment. Finally, the number of HRF was predictive for both BCVA improvement and a CRT reduction of less than 100 μm after treatment. No serious complications were reported during the study. Conclusion: Our study demonstrated the utility of OCT biomarkers as therapeutic predictors of ranibizumab treatment among DME eyes. |
format | Online Article Text |
id | pubmed-10053215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100532152023-03-30 Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections Chang, Yen-Chieh Huang, Yu-Te Hsu, Alan Y. Meng, Ping-Ping Lin, Chun-Ju Lai, Chun-Ting Hsia, Ning-Yi Chen, Huan-Sheng Tien, Peng-Tai Lin, Jane-Ming Chen, Wen-Lu Tsai, Yi-Yu Medicina (Kaunas) Article Background and Objectives: The identification of possible biomarkers that can predict treatment response among DME eyes is important for the individualization of treatment plans. We investigated optical coherence tomography (OCT)-based biomarkers that may predict the one-year real-life outcomes among diabetic macular edema (DME) eyes following treatment by intravitreal ranibizumab (IVR) injections. Materials and Methods: A total of 65 eyes from 35 treatment-naïve patients with DME treated with ranibizumab injection were recruited. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP), and OCT scans were retrospectively recorded at baseline before treatment and at 3 months, 6 months, and 12 months after treatment. The OCT scans were evaluated for biomarkers of interest, which included central retinal thickness (CRT), amount and locations of hyperreflective foci (HRF), subretinal fluid (SRF), intraretinal cysts (IRC), large outer nuclear layer cyst (LONLC), ellipsoid zone disruption (EZD), disorganization of retinal inner layers (DRIL), hard exudates (HE), epiretinal membrane (ERM), and vitreomacular interface (VMI). Correlations between these OCT biomarkers and outcome measures (visual and structural) were statistically analyzed. Results: A total of 65 eyes from 35 patients with DME were enrolled. The mean age was 64.2 ± 10.9 years old. Significant improvement in terms of mean BCVA (p < 0.005) and mean CRT was seen at final follow-up compared to baseline. The biomarkers of DRIL, LONLC, and SRF were found to be predictive for at least 50 μm CRT reduction after treatment (with odds ratio of 8.69, 8.5, and 17.58, respectively). The biomarkers of IRC, LONLC, and SRF were predictive for significant improvement in terms of BCVA and CRT after treatment. Finally, the number of HRF was predictive for both BCVA improvement and a CRT reduction of less than 100 μm after treatment. No serious complications were reported during the study. Conclusion: Our study demonstrated the utility of OCT biomarkers as therapeutic predictors of ranibizumab treatment among DME eyes. MDPI 2023-03-21 /pmc/articles/PMC10053215/ /pubmed/36984630 http://dx.doi.org/10.3390/medicina59030629 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chang, Yen-Chieh Huang, Yu-Te Hsu, Alan Y. Meng, Ping-Ping Lin, Chun-Ju Lai, Chun-Ting Hsia, Ning-Yi Chen, Huan-Sheng Tien, Peng-Tai Lin, Jane-Ming Chen, Wen-Lu Tsai, Yi-Yu Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections |
title | Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections |
title_full | Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections |
title_fullStr | Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections |
title_full_unstemmed | Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections |
title_short | Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections |
title_sort | optical coherence tomography biomarkers in predicting treatment outcomes of diabetic macular edema after ranibizumab injections |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053215/ https://www.ncbi.nlm.nih.gov/pubmed/36984630 http://dx.doi.org/10.3390/medicina59030629 |
work_keys_str_mv | AT changyenchieh opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections AT huangyute opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections AT hsualany opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections AT mengpingping opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections AT linchunju opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections AT laichunting opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections AT hsianingyi opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections AT chenhuansheng opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections AT tienpengtai opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections AT linjaneming opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections AT chenwenlu opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections AT tsaiyiyu opticalcoherencetomographybiomarkersinpredictingtreatmentoutcomesofdiabeticmacularedemaafterranibizumabinjections |